BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 34539652)

  • 1. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.
    Qiu H; Shao Z; Wen X; Jiang J; Ma Q; Wang Y; Huang L; Ding X; Zhang L
    Front Immunol; 2021; 12():716710. PubMed ID: 34539652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
    Gao A; Sun Y; Peng G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
    Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
    Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
    Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
    J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
    Makuku R; Khalili N; Razi S; Keshavarz-Fathi M; Rezaei N
    J Immunol Res; 2021; 2021():6661406. PubMed ID: 33681388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-G/LILRBs: A Cancer Immunotherapy Challenge.
    Carosella ED; Gregori S; Tronik-Le Roux D
    Trends Cancer; 2021 May; 7(5):389-392. PubMed ID: 33563576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.
    Hu J; Xiao Q; Dong M; Guo D; Wu X; Wang B
    Front Immunol; 2020; 11():593219. PubMed ID: 33329583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
    Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
    Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.
    Molgora M; Esaulova E; Vermi W; Hou J; Chen Y; Luo J; Brioschi S; Bugatti M; Omodei AS; Ricci B; Fronick C; Panda SK; Takeuchi Y; Gubin MM; Faccio R; Cella M; Gilfillan S; Unanue ER; Artyomov MN; Schreiber RD; Colonna M
    Cell; 2020 Aug; 182(4):886-900.e17. PubMed ID: 32783918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.
    Gao A; Liu X; Lin W; Wang J; Wang S; Si F; Huang L; Zhao Y; Sun Y; Peng G
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
    Ayala-Mar S; Donoso-Quezada J; González-Valdez J
    J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
    Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
    Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
    Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
    World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
    Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
    Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
    Shaver KA; Croom-Perez TJ; Copik AJ
    Front Immunol; 2021; 12():679117. PubMed ID: 33995422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normalization Cancer Immunotherapy for Melanoma.
    Vesely MD; Chen L
    J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
    Meng Q; He J; Zhong L; Zhao Y
    Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.